Drugs Containing Excipient (Inactive Ingredient) MICROCRYSTALLINE CELLULOSE

Branded drugs containing MICROCRYSTALLINE CELLULOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ApoPharma USA Inc	ALKERAN	melphalan	52609-0001	MICROCRYSTALLINE CELLULOSE
Hikma Pharmaceuticals USA Inc	DISKETS	methadone hydrochloride	0054-4538	MICROCRYSTALLINE CELLULOSE 101
Azurity Pharmaceuticals Inc	WIDAPLIK	telmisartan, amlodipine and indapamide	24338-001	MICROCRYSTALLINE CELLULOSE 101	2038-01-23
Jacobus Pharmaceutical CompanyInc	RUZURGI	amifampridine	49938-110	MICROCRYSTALLINE CELLULOSE 101	2026-05-06

Generic drugs containing MICROCRYSTALLINE CELLULOSE excipient

Company	Ingredient	NDC	Excipient
Rugby Laboratories	loratadine	0536-1092	MICROCRYSTALLINE CELLULOSE
Rugby Laboratories	budesonide	0536-1112	MICROCRYSTALLINE CELLULOSE
Rite Aid Corporation	ranitidine hydrochloride	11822-6051	MICROCRYSTALLINE CELLULOSE
Rite Aid Corporation	cetirizine hydrochloride	11822-6053	MICROCRYSTALLINE CELLULOSE

Microcrystalline Cellulose Market Dynamics, Financial Trajectory, Suppliers, and Intellectual Property

Last updated: August 7, 2026

Microcrystalline cellulose (MCC) is a mature, globally traded pharmaceutical excipient used primarily as a tablet filler, dry binder, disintegrant, and carrier. The market is structurally attractive because MCC is embedded in generic-drug production, nutraceuticals, and direct-compression formulations. Growth is moderate rather than explosive, with demand driven by oral solid-dose medicines, emerging-market manufacturing, and higher use of direct compression.

Published market estimates generally place the global MCC market near the low-single-digit billions of dollars, although methodologies differ by whether food, cosmetics, and industrial applications are included. Pharmaceutical-grade MCC represents the highest-value segment because it requires tighter specifications, validated manufacturing, regulatory documentation, and customer qualification.

What is microcrystalline cellulose used for in pharmaceutical manufacturing?

MCC is a purified, partially depolymerized cellulose produced mainly from wood pulp or other cellulose sources. It is identified by CAS number 9004-34-6 and is available in multiple particle-size, moisture, and flowability grades.

In pharmaceutical formulations, MCC is used for:

• Direct compression of tablets
• Wet and dry granulation
• Dilution and bulking
• Dry binding
• Tablet disintegration support
• Capsule filling
• Carrier systems for poorly compactable powders
• Co-processed excipients
• Nutraceutical and dietary-supplement tablets

Common commercial grades include Avicel PH-101, PH-102, PH-200, PH-301, and PH-302; DFE Pharma’s Comprecel grades; JRS Pharma’s VIVAPUR grades; and Roquette’s CEOLUS grades. Grade selection depends on particle size, bulk density, flow, compactability, moisture sensitivity, and tablet hardness requirements.

MCC is particularly important in direct compression because it can improve powder compactability without requiring a wet granulation step. That reduces processing time, solvent use, equipment requirements, and manufacturing complexity.

How large is the microcrystalline cellulose market?

Third-party market studies typically estimate the global MCC market at approximately $1 billion to $1.5 billion in recent years, with forecast compound annual growth rates commonly ranging from 5% to 8%, depending on the inclusion of food and industrial applications (Grand View Research, 2024; MarketsandMarkets, 2024).

The pharmaceutical and nutraceutical segments account for a substantial portion of value because they use higher-specification grades and require longer customer-qualification cycles. Food-grade and industrial MCC generate significant volume but generally face lower selling prices.

Market factor	Current market effect
Generic oral solid-dose production	Creates stable baseline demand
Direct compression	Increases use of higher-functionality grades
Nutraceutical tablets	Expands volume but increases price competition
Biologics	Limited direct effect because MCC is mainly used in oral solid doses
Emerging-market pharmaceutical production	Supports long-term unit growth
Pulp and energy costs	Affect supplier margins
Regulatory qualification	Protects incumbent suppliers after approval
Co-processed excipients	Increases value per kilogram

The market is fragmented by geography but concentrated among a small group of recognized pharmaceutical excipient suppliers. Qualification requirements make it difficult for low-cost producers to displace established suppliers in regulated markets.

What is the financial trajectory for microcrystalline cellulose suppliers?

The expected financial trajectory is moderate volume growth, stable-to-improving demand for premium grades, and continued margin pressure on standardized products.

MCC suppliers benefit from recurring consumption. Once a pharmaceutical manufacturer validates an excipient grade in a commercial formulation, substitution can require comparative development work, stability assessment, regulatory review, and manufacturing requalification. This creates customer retention and supports pricing for validated pharmaceutical grades.

The main financial drivers are:

1. Growth in generic tablet and capsule production.
2. Increased adoption of direct compression.
3. Demand for low-moisture and high-flow grades.
4. Expansion of co-processed excipients.
5. Regional manufacturing growth in India, China, Southeast Asia, Latin America, and the Middle East.
6. Price increases linked to pulp, electricity, labor, logistics, and quality-system costs.

The main financial risks are:

• Commodity-like pricing for standard grades
• Pulp-price volatility
• Energy-intensive drying and milling operations
• Customer concentration among large generic-drug manufacturers
• Substitution by lactose, dibasic calcium phosphate, mannitol, starches, silicified excipients, and other direct-compression carriers
• Qualification barriers that slow customer wins
• Regulatory costs for maintaining multiple global grades

Public-company disclosures rarely report MCC revenue as a separate line item. IFF, Roquette, DFE Pharma, and JRS Pharma generally report broader pharmaceutical excipient or health-sciences businesses. As a result, product-level revenue and EBITDA estimates for MCC are not reliably available from public filings.

Which companies manufacture pharmaceutical-grade microcrystalline cellulose?

The leading recognized suppliers include IFF, DFE Pharma, JRS Pharma, and Roquette. Regional manufacturers in China, India, and other Asian markets add capacity, particularly for standard grades and local-market applications.

Company	Major MCC brand or product family	Commercial position
IFF	Avicel	Established global pharmaceutical and food excipient supplier
DFE Pharma	Comprecel	Pharmaceutical excipient specialist with global customer coverage
JRS Pharma	VIVAPUR	Broad excipient portfolio and strong formulation-development support
Roquette	CEOLUS	Large global excipient platform and direct-compression focus
Regional Asian suppliers	Multiple local brands	Price-competitive supply, especially in domestic and emerging markets

IFF’s Avicel franchise is one of the best-known MCC brands globally. DFE Pharma, JRS Pharma, and Roquette compete through formulation support, technical service, global documentation, supply reliability, and product breadth rather than price alone.

The competitive advantage is often operational rather than patent-based. Pharmaceutical customers value consistent particle-size distribution, moisture profile, bulk density, flow, microbial control, traceability, and batch-to-batch performance.

How does pharmaceutical-grade MCC compare with food-grade MCC?

Pharmaceutical-grade MCC commands a premium because it must meet tighter quality, documentation, and change-control expectations.

Attribute	Pharmaceutical-grade MCC	Food-grade MCC
Primary customers	Drug manufacturers and contract manufacturers	Food, supplement, and ingredient companies
Documentation	Extensive regulatory and quality documentation	Generally less complex
Qualification	Often formulation-specific and site-specific	Usually faster and less restrictive
Price	Higher	Lower
Change control	Highly formalized	Less demanding in many applications
Manufacturing controls	Pharmaceutical GMP expectations	Food-grade controls
Margin profile	Higher but quality-cost intensive	More exposed to commodity pricing

A food-grade product may not be acceptable for a pharmaceutical formulation even when the chemical identity is similar. Drug manufacturers typically require compliance with relevant pharmacopeial monographs, supplier audits, impurity controls, elemental-impurity assessments, microbial specifications, and documented change-control procedures.

What regulatory status does microcrystalline cellulose have?

MCC is an established excipient recognized in major pharmaceutical markets. It is included in compendial standards such as the United States Pharmacopeia-National Formulary and the European Pharmacopoeia. The U.S. Food and Drug Administration’s Inactive Ingredient Database includes cellulose-derived excipients used in approved drug products (FDA, 2024).

MCC does not require an independent FDA premarket approval as a drug because it is an inactive ingredient rather than an active pharmaceutical ingredient. Its regulatory acceptance depends on the finished dosage form, route of administration, concentration, grade, and prior approved use.

Regulatory considerations include:

• USP-NF and Ph. Eur. compliance
• FDA Inactive Ingredient Database status
• Supplier Drug Master File or equivalent regulatory documentation
• GMP manufacturing
• Microbial and endotoxin controls where applicable
• Residual-processing chemical controls
• Elemental-impurity risk assessment
• Nitrosamine and extractables/leachables assessments where relevant
• Change-control notification

For a new dosage form, route, or concentration, a sponsor must establish that the proposed use is appropriate and supported by safety and quality data. MCC is primarily used in oral solid dosage forms; its regulatory position is less straightforward for novel routes of administration.

What patents protect microcrystalline cellulose?

The basic MCC composition is not protected by a meaningful, enforceable composition patent in major pharmaceutical markets. MCC has been commercially used for decades, and the core material is generally regarded as off-patent.

Patent activity remains relevant in four areas:

Manufacturing methods

Suppliers may seek protection for:

• Pulp pretreatment
• Hydrolysis and depolymerization conditions
• Particle-size control
• Drying methods
• Moisture management
• Surface modification
• High-density or high-flow grades
• Continuous manufacturing processes

Co-processed excipients

Patent claims may cover combinations of MCC with:

• Colloidal silicon dioxide
• Crospovidone
• Starch
• Lactose
• Mannitol
• Calcium phosphate
• Superdisintegrants
• Other binders or flow aids

Formulation patents

Drug-product sponsors may claim a particular MCC grade or MCC-containing formulation in a tablet, capsule, chewable, orally disintegrating tablet, or controlled-release dosage form.

Method-of-use patents

MCC can appear in claims directed to manufacturing processes, tablet-compression methods, or treatment products where the excipient contributes to a defined performance profile.

These patents usually protect a grade, process, combination, or finished formulation. They do not generally create broad exclusivity over MCC itself.

What is the Orange Book status of microcrystalline cellulose?

MCC has no Orange Book listing because the Orange Book identifies approved drug products and their patents or regulatory exclusivity, not excipients as standalone commercial products.

There is no MCC Paragraph IV pathway. Paragraph IV certifications apply to generic applicants challenging patents listed for a reference drug. A generic-drug applicant could challenge a formulation patent that includes MCC, but the challenge would concern the finished drug product, not the general availability of MCC.

MCC also has no biologic exclusivity period and no biosimilar-specific patent framework. Biosimilar risk is therefore not directly relevant to the excipient market.

How strong is the intellectual-property estate for microcrystalline cellulose?

The core MCC patent estate is weak because the base material is mature and broadly available. Supplier-level protection is stronger at the process and grade level.

IP category	Strength	Commercial relevance
Basic MCC composition	Low	Limited exclusivity
Manufacturing process	Moderate	Can protect quality and cost advantages
Particle engineering	Moderate	Supports premium grades
Co-processed excipients	Moderate to strong	Can differentiate performance
Finished-drug formulation	Drug-specific	May delay generic entry
Trade secrets and know-how	High practical value	Protects process consistency and scale-up
Regulatory documentation	Moderate	Raises switching costs

Trade secrets, process know-how, site qualification, and customer history may be more valuable than patents. A supplier with validated performance data and a reliable global supply chain can retain business even where competitors have legally equivalent products.

What manufacturing barriers affect MCC supply?

The principal barriers are process control, raw-material quality, scale, and regulatory reliability.

MCC production generally requires:

1. Controlled cellulose feedstock.
2. Chemical treatment or hydrolysis.
3. Washing and purification.
4. Drying.
5. Milling and particle engineering.
6. Classification and blending.
7. Packaging under controlled conditions.
8. Testing against pharmacopeial and customer specifications.

Wood-pulp quality and availability affect color, ash, degree of polymerization, moisture, and impurity profiles. Drying and milling conditions influence flow, compressibility, particle morphology, and tablet performance.

Pharmaceutical customers often qualify a specific manufacturing site, not only a supplier name. A site change or major process change can trigger comparative testing, stability work, regulatory notifications, or revalidation. This limits rapid switching and supports incumbent suppliers.

When could generic or alternative excipient competition affect MCC pricing?

Competition is strongest in standard MCC grades used in high-volume generic tablets. Pricing pressure rises when:

• Multiple suppliers meet the same pharmacopeial specifications.
• Customers have qualified alternate sources.
• Demand growth slows.
• Pulp and freight costs fall.
• Regional producers expand into regulated markets.
• Large generic manufacturers consolidate purchasing.

Premium grades are more defensible because they deliver measurable benefits in flow, compactability, tablet strength, lubricant sensitivity, or low-moisture processing. Co-processed systems can command higher prices but must demonstrate a clear formulation advantage.

Substitution risk is formulation-specific. Lactose is widely used as a filler, but it has different compressibility and moisture behavior. Mannitol can support orally disintegrating and chewable tablets but is usually more expensive. Dibasic calcium phosphate has strong compaction properties but may be unsuitable for acid-sensitive or chelation-sensitive formulations. Starch and pregelatinized starch offer different binding and disintegration profiles.

What licensing deals and litigation affect the MCC market?

There is no widely reported, industry-defining patent settlement comparable to those seen in branded pharmaceuticals. Publicly disclosed licensing arrangements generally relate to distribution, technology access, formulation systems, or broader excipient portfolios rather than a license to the basic MCC molecule.

Litigation risk is concentrated in:

• Supplier claims over proprietary manufacturing processes
• Trade-secret disputes
• Contract and supply disagreements
• Finished-drug formulation patents
• Co-processed excipient claims
• Product liability or quality disputes

Because MCC itself is an established excipient, market entry is more likely to be constrained by customer qualification and regulatory compliance than by a blocking patent.

How does MCC compare with competing pharmaceutical excipients?

Excipient	Relative strengths	Main limitations
MCC	Excellent dry binding and direct compression	Moisture sensitivity and formulation incompatibilities
Lactose	Low cost and broad use	Maillard reaction risk with some amines
Mannitol	Good mouthfeel and low hygroscopicity	Higher cost and different compaction behavior
Dibasic calcium phosphate	Strong compaction and low moisture uptake	Density and incompatibility constraints
Pregelatinized starch	Binding and disintegration support	Different flow and moisture profile
Copovidone	Binding and solubility support	Higher cost and different processing requirements

MCC is most defensible where formulation developers need robust tablet compaction without wet granulation. It is less dominant in formulations where moisture sensitivity, density, taste, chemical compatibility, or rapid disintegration dictates excipient selection.

What is the outlook for MCC revenue and market growth?

The base case is steady mid-single-digit market growth through the end of the decade, with premium-grade revenue growing faster than commodity-grade volume.

Period	Expected market direction
2024-2025	Stable demand, inventory normalization, continued generic-drug growth
2026-2027	Higher adoption of direct compression and engineered grades
2028 onward	Moderate expansion with regional capacity growth and ongoing substitution pressure

Revenue growth should come from price, mix, and volume. Premium pharmaceutical grades and co-processed systems are likely to produce better margins than standard MCC. Suppliers with manufacturing sites in multiple regions can reduce logistics exposure and improve continuity-of-supply performance.

The largest downside risks are a prolonged slowdown in oral solid-dose production, aggressive low-cost capacity expansion, substitution by alternative fillers, and raw-material inflation that cannot be passed through to customers.

Key Takeaways

• MCC is a mature, high-volume pharmaceutical excipient with recurring demand from tablets, capsules, generics, and nutraceuticals.
• Global market estimates generally fall near $1 billion to $1.5 billion, with forecast growth commonly estimated at 5% to 8%.
• IFF, DFE Pharma, JRS Pharma, and Roquette are among the principal global suppliers.
• Pharmaceutical-grade MCC has better pricing and retention characteristics than food-grade or industrial material.
• The basic MCC composition is broadly off-patent. Competitive protection comes from manufacturing processes, particle engineering, co-processed systems, know-how, and regulatory qualification.
• MCC has no standalone Orange Book listing, Paragraph IV pathway, or biosimilar exclusivity issue.
• Direct compression, generic-drug manufacturing, and premium engineered grades support the financial outlook.
• Standard grades face price competition from regional suppliers and alternative excipients.
• Supplier revenue is difficult to isolate because public companies generally report broader excipient or health-sciences segments.
• Manufacturing reliability and customer qualification are stronger barriers than basic composition patents.

FAQs

Is microcrystalline cellulose a high-margin pharmaceutical excipient?

Premium pharmaceutical grades and co-processed MCC products can support attractive margins. Standard grades face greater price competition and are more sensitive to pulp, energy, and freight costs.

Can microcrystalline cellulose be replaced by lactose in tablets?

Yes, but substitution requires formulation development. Lactose and MCC differ in compressibility, moisture behavior, density, chemical compatibility, and disintegration performance.

Does microcrystalline cellulose create drug patent infringement risk?

MCC itself generally does not create patent infringement risk. Risk may arise from a finished-drug formulation, manufacturing process, or co-processed excipient patent that includes MCC.

Is China a major competitive threat to established MCC suppliers?

Chinese producers can pressure prices in standard grades and regional markets. Entry into heavily regulated markets remains more difficult because suppliers must demonstrate consistent quality, documentation, GMP controls, and customer-specific performance.

Is MCC suitable for biologic drug formulations?

MCC is primarily used in oral solid-dose products and has limited direct relevance to injectable biologics. Its role is more relevant to tablets, capsules, oral delivery systems, and nutraceutical products than to biosimilar manufacturing.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.

2. Food and Drug Administration. (2024). Inactive Ingredient Database. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. Grand View Research. (2024). Microcrystalline cellulose market size, share and trends analysis report. Grand View Research.

4. International Pharmaceutical Excipients Council. (2023). The IPEC excipient information package. IPEC.

5. MarketsandMarkets. (2024). Microcrystalline cellulose market by source, application, and region. MarketsandMarkets.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

7. International Flavors & Fragrances Inc. (2024). Annual report. IFF.

8. Roquette. (2024). Pharmaceutical excipients and drug-delivery solutions. Roquette.

9. DFE Pharma. (2024). Pharmaceutical excipient product portfolio. DFE Pharma.

10. JRS Pharma. (2024). Pharmaceutical excipients product portfolio. JRS Pharma.